Will AstraZeneca stock hold above GBX12,876 support as sellers control the short-term trend?
AstraZeneca (AZN) stock is trading at GBX13,300, marking a 2.54% drop on the day. The price sits below its key moving averages, reflecting persistence of bearish momentum in the short, medium, and long term.
Highlights
- The FDA has granted Priority Review to AstraZeneca's sonesitatug vedotin for advanced gastric and esophageal cancers, potentially enabling accelerated U.S. market access.
- AstraZeneca renewed its partnership with Tempus AI under a $200 million agreement for advanced clinical data analytics through 2031.
- Shares of AstraZeneca remain under strong selling pressure, trading below key moving averages with momentum indicators signaling a likely move toward the GBX12,876 to GBX13,723 range.
Regulatory milestones and R&D deals countered by ongoing selling pressure
The grant of Priority Review status by the U.S. Food and Drug Administration for AstraZeneca's sonesitatug vedotin (Sone-Ve) targeting advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma represents a significant regulatory milestone that could accelerate future U.S. market access for this cancer therapy, according to Marketscreener. The expedited FDA process heightens the potential for earlier revenue generation from AZN's oncology portfolio, though any impact will be realized only following regulatory approval. Additionally, AstraZeneca has renewed its partnership with Tempus AI through a $200 million master services agreement extending to the end of 2031, as reported by Benzinga, which secures access to advanced clinical data analytics in support of R&D initiatives. Despite these positive developments, price action has remained under broader selling pressure.
Oversold momentum and resistance cap price amid continued bearish bias
Technically, AZN is trading below the H1 SMA-20 at GBX13,587, H1 SMA-50 at GBX13,819, and the D1 SMA-200 at GBX13,439, with the Ichimoku Kijun at GBX13,606 acting as immediate resistance. Momentum indicators show MACD and ADX with sell signals, while RSI, Stoch RSI, and CCI are all verified in oversold zones, indicating possible exhaustion in selling but not confirming a reversal. Bull/Bear Power remains negative at -150.2, and the Awesome Oscillator also reinforces the prevailing bearish tone. The price is near today's low, reflecting moderate session volatility and ongoing seller dominance.
Downside breakout risk elevated as range-bound volatility prevails
In the short term, AZN is expected to consolidate within the GBX12,876 to GBX13,723 range, representing the typical volatility band relative to current levels. With a 79% probability assigned to a downward move and 21% to an upward move, a breakout below support at GBX12,876 would likely trigger further declines. Conversely, a bullish reversal scenario requires a close above immediate resistance at GBX13,606 to signal renewed buying interest.
Earlier, analysts noted that AstraZeneca shares were experiencing sustained bearish pressure despite positive corporate developments. The current technical setup reinforces downside risks, making GBX12,876 a critical support level that traders should monitor for the potential of an accelerated decline.